FORE US Bio
FORE US Bio Inc.
Fore Biotherapeutics, also known as Fore Bio, is a precision oncology firm focused on creating innovative treatment solutions for patients suffering from difficult-to-treat cancers, particularly those with specific genetic mutations associated with established oncology targets. The company aims to bridge the gap in cancer treatment by developing therapies tailored for patients with unaddressed tumor mutations.
Products & Team
Plixorafenib
Plixorafenib, previously known as FORE8394, is an investigational next-generation BRAF inhibitor designed to target a broader spectrum of BRAF gene alterations in cancer cells compared to traditional BRAF inhibitors. This next-gen therapy is currently under investigation for its potential in treating various solid tumors and brain malignancies caused by BRAF mutations.
Plixorafenib offers hope to cancer patients with specific BRAF mutations who currently have limited or no effective treatments by providing a targeted precision medicine approach.
The primary issues addressed include the lack of effective treatments for patients with specific genetic mutations that are not targeted by existing therapies, leading to a significant number of unserved patients with limited options.